non-bacterial prostatitis

non-bacterial prostatitis

Urology Inflammation of the prostate of abrupt onset often caused Chlamydia spp or Ureaplasma spp Clinical Associated with or follows UTIs, urethritis, or epididymitis, more common in ♂ age 20 to 35, who have unsafe sex and/or multiple sexual partners. See Prostatitis.
Mentioned in ?
References in periodicals archive ?
Exclusion criteria included proven prostate cancer, histological findings of non-bacterial prostatitis, pathological urinary sediment, positive bacterial cultures of urine, consumption of foods rich in soy isoflavanoids, dietary supplements of any kind and medications with possible effects on prostate health.
22) Moreover, those authors showed a relationship between the severity of varicocele on Doppler ultrasonography and seminal fluid IL-8 levels, which is an indicator of non-bacterial prostatitis.
Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with (alpha)-blocking agent doxazosin; Versus placebo.
Tamsulosin treatment of chronic non-bacterial prostatitis.
This was followed by 6 months of severe non-bacterial prostatitis.
The first clinical trial results evaluating an alpha-blocker for the treatment of non-bacterial prostatitis were presented Saturday at the annual meeting of the American Urological Association.
Currently, non-bacterial prostatitis is typically treated by using non-steroidal anti- inflammatory drugs (NSAIDs), which reduce inflammation and can help alleviate pain, or alpha-blockers, which relax smooth muscle in the prostate and help relieve urinary symptoms.
These results demonstrate the efficacy of ML-04 for the treatment of chronic, non-bacterial prostatitis.
The NIH multi-site, double-blinded, placebo-controlled, randomized study is the first designed to evaluate the efficacy, safety and tolerability of an alpha-blocker (FLOMAX, tamsulosin HCL) and an oral antibiotic (CIPRO, ciprofloxacin) in combination as compared to each agent alone for the treatment of non-bacterial prostatitis, which accounts for as many as 95 percent of all prostatitis cases.
The NIH study will be the first to evaluate the safety and efficacy of combination therapy of FLOMAX, the leading alpha-blocker used to treat benign prostatic hyperplasia (BPH), plus CIPRO, an antibiotic therapy commonly prescribed to treat bacterial prostatitis, in men of all ages with non-bacterial prostatitis.
BGM-24 is a plant-extracted, proprietary drug candidate to treat symptoms of Benign Prostatic Hyperplasia (BPH), a non-cancerous enlargement of the innermost part of the prostate, and may also be considered for the treatment of chronic non-bacterial Prostatitis and Prostatodynia.
In the urology setting, ALZA will be supporting studies to explore the role of Elmiron(R) in the treatment of chronic pelvic pain syndrome, or non-bacterial prostatitis, a condition that affects between 6 million and 12 million men in the United States.